Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Tonix Pharmaceuticals Holding (TNXP) EBIAT (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of EBIAT data on record, last reported at -$31.8 million in Q3 2025.

  • For Q3 2025, EBIAT fell 104.68% year-over-year to -$31.8 million; the TTM value through Sep 2025 reached -$98.7 million, up 30.29%, while the annual FY2024 figure was -$136.7 million, 17.18% down from the prior year.
  • EBIAT reached -$31.8 million in Q3 2025 per TNXP's latest filing, down from -$28.3 million in the prior quarter.
  • Across five years, EBIAT topped out at -$15.6 million in Q3 2024 and bottomed at -$77.3 million in Q2 2024.
  • Average EBIAT over 3 years is -$30.0 million, with a median of -$28.0 million recorded in 2023.
  • Peak YoY movement for EBIAT: tumbled 172.66% in 2024, then surged 63.4% in 2025.
  • A 3-year view of EBIAT shows it stood at -$27.3 million in 2023, then grew by 17.72% to -$22.5 million in 2024, then tumbled by 41.62% to -$31.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIAT were -$31.8 million in Q3 2025, -$28.3 million in Q2 2025, and -$16.1 million in Q1 2025.